Overview of Datasets
For detailed description of the evaluation the Novartis Access program, please refer to the published study protocol or ClinicalTrials.gov. The data collection instruments and the data dictionary are also available here.
Datasets from baseline and midline are now available. Baseline and midline studies each have one dataset for households and one for health facilities and private drug sellers. Baseline data were collected from eight counties in Kenya in September 2016. Midline data were collected in January 2018. Each data set comes with a data dictionary that describes all included variables. If you have any questions regarding the data, please contact Peter Rockers at firstname.lastname@example.org or Richard Laing at email@example.com.
Baseline household data: Data were collected through face-to-face interviews with individual adult patients who reported having been diagnosed with asthma, breast cancer, diabetes or cardiovascular disease (heart failure, hyperlipidemia, or hypertension) and prescribed at least one medicine for their condition. This dataset contains observations from 639 patients.
Baseline health facility data: Data were collected through face-to-face interviews with staff at 272 health facilities (59 public health facilities, 78 private non-profit health facilities, 135 private-for-profit drug outlets (chemists)) in the eight study counties. Key variables include price and availability data on 15 generic equivalents of Novartis Access medicines and 13 other essential medicines (tracer medicines which have been used as reference medicines to evaluate the availability of price of medicines in different healthcare systems).
Midline household data: The midline household data set contains follow-up data from 572 of the patients interviewed at baseline. Midline questions and methods are similar to those used at baseline.
Midline health facility data: The midline health facility data set contains follow-up data from 225 of the outlets interviewed at baseline (61 public health facilities, 67 private non-profit health facilities, 97 private-for-profit drug outlets). Midline questions and methods are similar to those used at baseline.
Endline household data: The endline household data set contains follow-up data from 516 of the patients interviewed at baseline. Endline questions and methods are similar to those used at baseline.
Endline health facility data: The endline health facility data set contains follow-up data from 221 of the outlets interviewed at baseline (57 public health facilities, 70 private non-profit health facilities, 94 private-for-profit drug outlets). Endline questions and methods are similar to those used at baseline.
Please provide the following information below so that we may send you the datasets via email.
These datasets may not be used for the purpose of identifying any study participant, sponsor or for any marketing or commercial activity. The use of the data by researchers should comply with local, institutional and international standards on the protection of human research subjects. If you are using this data for a peer reviewed publication, we would appreciate it if you could let us know so we can post a link to your publication at this site. Please email Richard Laing at (firstname.lastname@example.org) with details of the publication. The use of this data should be appropriately cited.
Boston University. Evaluation of Novartis Access in Kenya [Dataset], Boston, Massachusetts: Boston University [Distributor]. 2017.
Boston University owns these datasets and has made them publicly available for researchers and policy makers. Boston University reserves the right to update these datasets without prior notice.
Boston University makes no warranties of any kind, express or implied, including, without limitation, warranties concerning the datasets or the merchantability, or fitness for a particular purpose of the datasets. Boston University shall not be liable for any indirect, consequential, or other damages resulting from the use of the datasets.